Genetic alterations and personalized medicine in melanoma: progress and future prospects.
暂无分享,去创建一个
[1] D. Hoon,et al. Epigenetic biomarkers in skin cancer. , 2014, Cancer letters.
[2] A. D. Van den Abbeele,et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[4] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[5] Bart Spiessens,et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Kefford,et al. Secondary c‐Kit mutations confer acquired resistance to RTK inhibitors in c‐Kit mutant melanoma cells , 2013, Pigment cell & melanoma research.
[7] D. Schadendorf,et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours , 2013, British Journal of Cancer.
[8] N. Naus,et al. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11 , 2013, British Journal of Cancer.
[9] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[10] Joshua M. Stuart,et al. Integrated genomic characterization of endometrial carcinoma , 2013, Nature.
[11] D. Schadendorf,et al. Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas , 2013, Clinical Cancer Research.
[12] Ashley M. Zehnder,et al. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors , 2013, Nature Medicine.
[13] M. Kretz,et al. Abstract LB-248: BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. , 2013 .
[14] L. Heinzerling,et al. Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice , 2013, British Journal of Cancer.
[15] J. William Harbour,et al. The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma , 2013, PLoS currents.
[16] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.
[17] D. Schadendorf,et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.
[18] K. Flaherty,et al. Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.
[19] K. Aldape,et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. , 2013, The Journal of molecular diagnostics : JMD.
[20] C. Berking,et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.
[21] D. Schadendorf,et al. TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.
[22] Thomas Krausz,et al. BAP1 and cancer , 2013, Nature Reviews Cancer.
[23] Sarah-Jane Schramm,et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. , 2013, The Journal of investigative dermatology.
[24] J. Sosman,et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Weeraratna,et al. Faculty Opinions recommendation of Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. , 2012 .
[26] R. Scolyer,et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma , 2012, The British journal of dermatology.
[27] E. Nagore,et al. Fluorescence in situ hybridization for the differential diagnosis between Spitz naevus and spitzoid melanoma , 2012, Histopathology.
[28] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[29] V. Sondak,et al. 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy? , 2012, Scientific Reports.
[30] Ivana K. Kim,et al. High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. , 2012, Investigative ophthalmology & visual science.
[31] Jin Hyun Cho,et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration , 2012, Investigational New Drugs.
[32] J. Wilmott,et al. Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine , 2012, Molecular Cancer Therapeutics.
[33] M. Birtwistle,et al. Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma , 2012, PloS one.
[34] C. Ng,et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.
[35] K. Flaherty,et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[36] K. Flaherty,et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[37] T. Mentzel,et al. A Proposal for Improving Multicolor FISH Sensitivity in the Diagnosis of Malignant Melanoma Using New Combined Criteria , 2012, The American Journal of dermatopathology.
[38] M. van Engeland,et al. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. , 2012, Biochimica et biophysica acta.
[39] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[40] A. Sivachenko,et al. A Landscape of Driver Mutations in Melanoma , 2012, Cell.
[41] Matthew J. Davis,et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.
[42] Jane Fridlyand,et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors , 2012, Nature.
[43] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[44] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[45] L. Cerroni,et al. A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression , 2012, The American journal of surgical pathology.
[46] R. Ádány,et al. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization , 2012, Melanoma research.
[47] J. Guitart,et al. A Highly Specific and Discriminatory FISH Assay for Distinguishing Between Benign and Malignant Melanocytic Neoplasms , 2012, The American journal of surgical pathology.
[48] N. Grishin,et al. BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.
[49] M. Brown,et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial , 2012, The Lancet.
[50] P. Visca,et al. Melanoma molecular classes and prognosis in the postgenomic era. , 2012, The Lancet. Oncology.
[51] Lauren E Haydu,et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.
[52] D. Hazuda,et al. HIV-1 antiretroviral drug therapy. , 2012, Cold Spring Harbor perspectives in medicine.
[53] Trevor J Pugh,et al. Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.
[54] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[55] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[56] N. Bornfeld,et al. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study , 2012, British Journal of Cancer.
[57] M. Rosenblum,et al. GNAQ and GNA11 mutations in melanocytomas of the central nervous system , 2012, Acta Neuropathologica.
[58] Sarah-Jane Schramm,et al. Review and cross-validation of gene expression signatures and melanoma prognosis. , 2012, The Journal of investigative dermatology.
[59] K. Flaherty,et al. Major response to everolimus in melanoma with acquired imatinib resistance. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] B. Bastian,et al. Sunitinib Therapy for Melanoma Patients with KIT Mutations , 2012, Clinical Cancer Research.
[61] D. Melton,et al. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors , 2012, British Journal of Cancer.
[62] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[63] R. Sullivan,et al. Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.
[64] J. Guitart,et al. Enhanced Detection of Spitzoid Melanomas Using Fluorescence In Situ Hybridization With 9p21 as an Adjunctive Probe , 2012, The American journal of surgical pathology.
[65] K. Brown,et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.
[66] Tom Misteli,et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.
[67] S. Puig,et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.
[68] M. Abdel-Rahman,et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers , 2011, Journal of Medical Genetics.
[69] J. Becker,et al. Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.
[70] N. Cox,et al. Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.
[71] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] B. Bastian,et al. Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma , 2011, The American journal of surgical pathology.
[73] K. Flaherty,et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] C. Roberts,et al. SWI/SNF nucleosome remodellers and cancer , 2011, Nature Reviews Cancer.
[75] C. Sander,et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.
[76] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[77] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[78] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[79] Larry Norton,et al. Clinical implications of cancer self-seeding , 2011, Nature Reviews Clinical Oncology.
[80] M. Sznol,et al. A phase 2 trial of dasatinib in advanced melanoma , 2011, Cancer.
[81] S. Davis,et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.
[82] L. Cerroni,et al. Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases , 2011, Modern Pathology.
[83] V. Sondak,et al. Abstract 5370: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression , 2011 .
[84] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[85] R. Scolyer,et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site , 2011, Pigment cell & melanoma research.
[86] G. Mann,et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] T. Gajewski. Molecular profiling of melanoma and the evolution of patient-specific therapy. , 2011, Seminars in oncology.
[88] T. Hornyak,et al. EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of p21/CDKN1A Expression , 2011, Molecular Cancer Research.
[89] K. Flaherty,et al. Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma , 2011, Clinical Cancer Research.
[90] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[91] C. Der. Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2010 .
[92] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[93] A. Bowcock,et al. Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.
[94] D. Schadendorf,et al. Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.
[95] J. O'Brien,et al. Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.
[96] Andrew Menzies,et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.
[97] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[98] Li-E. Wang,et al. Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma , 2010, Clinical Cancer Research.
[99] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[100] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[101] I. L. de la Serna,et al. SWItching on the transcriptional circuitry in melanoma , 2010, Epigenetics.
[102] D. Schadendorf,et al. Somatic alterations in the melanoma genome: A high‐resolution array‐based comparative genomic hybridization study , 2010, Genes, chromosomes & cancer.
[103] Jan Koster,et al. NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome , 2010, Cell.
[104] C. Allis,et al. Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancers , 2010, Nature Reviews Cancer.
[105] S. Whittaker,et al. Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies , 2010, Science Translational Medicine.
[106] Alexander Roesch,et al. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.
[107] M. Wilm,et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB , 2010, Nature.
[108] M. Ringnér,et al. Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome , 2010, Clinical Cancer Research.
[109] A. Dobrovic,et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure , 2010, Pigment cell & melanoma research.
[110] J. Guitart,et al. Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. , 2010, Archives of dermatology.
[111] B. Győrffy,et al. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? , 2010, Clinical & Experimental Metastasis.
[112] J. Borovanský,et al. SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells. , 2010, Biochemical and biophysical research communications.
[113] Michael Krauthammer,et al. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma , 2010, BMC Medical Genomics.
[114] P. Helmbold,et al. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. , 2010, The Journal of investigative dermatology.
[115] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[116] Larry Norton,et al. Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.
[117] G. Reifenberger,et al. Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system , 2009, Acta Neuropathologica.
[118] J. López-Guerrero,et al. A germline mutation of p14/ARF in a melanoma kindred. , 2009, Melanoma research.
[119] Jimmy Lin,et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.
[120] G. Mills,et al. Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates , 2009, Molecular Cancer Therapeutics.
[121] R. DePinho,et al. BRafV600E cooperates with Pten silencing to elicit metastatic melanoma , 2009, Nature Genetics.
[122] H. Itoh,et al. Functions and Regulatory Mechanisms of Gq-Signaling Pathways , 2009, Neurosignals.
[123] E. Simpson,et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi , 2008, Nature.
[124] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[125] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[126] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[127] J. Fletcher,et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.
[128] Hong Wu,et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.
[129] Erwin G. Van Meir,et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. , 2008, Cancer research.
[130] M. Ross,et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma , 2008, British Journal of Cancer.
[131] C. Gedye,et al. Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma , 2008, Clinical Cancer Research.
[132] B. Bastian,et al. Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation , 2008, Pigment cell & melanoma research.
[133] T. Shioda,et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.
[134] F. Sera,et al. MC1R variants, melanoma and red hair color phenotype: A meta‐analysis , 2008, International journal of cancer.
[135] Jane Fridlyand,et al. Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.
[136] L. Akslen,et al. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma , 2008, Modern Pathology.
[137] A. D. Van den Abbeele,et al. Major response to imatinib mesylate in KIT-mutated melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[138] Justis P. Ehlers,et al. Integrative Genomic Analysis of Aneuploidy in Uveal Melanoma , 2008, Clinical Cancer Research.
[139] K. Hemminki,et al. MC1R variants associated susceptibility to basal cell carcinoma of skin: Interaction with host factors and XRCC3 polymorphism , 2007, International journal of cancer.
[140] J. N. Newton Bishop,et al. Genetics: what advice for patients who present with a family history of melanoma? , 2007, Seminars in oncology.
[141] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[142] K. Gow,et al. Melanoma in children and adolescents. , 2007, Surgical oncology.
[143] D. Bennett. How to make a melanoma: what do we know of the primary clonal events? , 2007, Pigment cell & melanoma research.
[144] I. Bièche,et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. , 2007, Cancer research.
[145] M. Trivett,et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.
[146] J. Gutkind,et al. G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.
[147] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[148] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[149] D. Pinkel,et al. MC1R germline variants confer risk for BRAF-mutant melanoma. , 2006, Science.
[150] L. Chin,et al. Malignant melanoma: genetics and therapeutics in the genomic era. , 2006, Genes & development.
[151] S. Puig,et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents , 2006, Journal of Medical Genetics.
[152] Alessandra Marini,et al. Epigenetic silencing of the PTEN gene in melanoma. , 2006, Cancer research.
[153] M. Atkins,et al. Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.
[154] A. Eggermont,et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. , 2006, Journal of the National Cancer Institute.
[155] L. Cannon-Albright,et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. , 2006, The Journal of investigative dermatology.
[156] J. Hepler,et al. Cell signalling diversity of the Gqα family of heterotrimeric G proteins , 2006 .
[157] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[158] J. A. Bishop,et al. A mutation hotspot at the p14ARF splice site , 2005, Oncogene.
[159] C. Johannessen,et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[160] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[161] D. Schadendorf,et al. Lack of clinical efficacy of imatinib in metastatic melanoma , 2005, British Journal of Cancer.
[162] D. Gutmann,et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. , 2005, Cancer research.
[163] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[164] Richard Marais,et al. The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.
[165] Justis P. Ehlers,et al. Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death , 2004, Cancer Research.
[166] Wei Zhang,et al. A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors , 2004, Cancer Research.
[167] L. Kanter,et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[168] K. Jöckel,et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. , 2003, Cancer research.
[169] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[170] J M Trent,et al. The genetics of cutaneous melanoma. , 2000, Clinics in laboratory medicine.
[171] N. Sampas,et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling , 2000, Nature.
[172] Keith D Wilkinson,et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression , 1998, Oncogene.
[173] D. Pinkel,et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. , 1998, Cancer research.
[174] P. Guldberg,et al. Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. , 1997, Cancer research.
[175] N. Bornfeld,et al. Prognostic implications of monosomy 3 in uveal melanoma , 1996, The Lancet.
[176] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[177] B. Dynlacht,et al. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition , 1995, Nature.
[178] J. Bartek,et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.
[179] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[180] S. Sprang,et al. Mechanism of GTP hydrolysis by G-protein alpha subunits. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[181] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[182] M. Skolnick,et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus , 1994, Nature Genetics.
[183] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[184] Koichiro R. Isshiki,et al. Chromosome 10 allelic loss in malignant melanoma , 1993, Genes, chromosomes & cancer.
[185] M. Skolnick,et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.
[186] N. Bornfeld,et al. Chromosomal aberrations defining uveal melanoma of poor prognosis , 1992, The Lancet.
[187] P. O’Connell,et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21 , 1990, Cell.
[188] P. O'Connell,et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.
[189] B. Brownstein,et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.
[190] P. O'Connell,et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.
[191] L. J. Veer,et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.
[192] Y. Ueyama,et al. B-raf, a new member of the raf family, is activated by DNA rearrangement , 1988, Molecular and cellular biology.
[193] T. Bonner,et al. Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[194] G. Currie,et al. Activation of N-ras in a human melanoma cell line , 1985, Molecular and cellular biology.
[195] L. Old,et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? , 1984, Nature.
[196] R. Lurz,et al. Two unrelated cell‐derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. , 1983, The EMBO journal.
[197] F H Reynolds,et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[198] C. Marshall,et al. Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1 , 1983, Nature.
[199] D. Anderson. Ceinical characteristics of the genetic variety of cutaneous melanoma in man , 1971, Cancer.
[200] Jochen K. Lennerz,et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair / fair skin background , 2012 .
[201] M. Smith,et al. Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma , 2011 .
[202] J. Troge,et al. Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.
[203] W. Cavenee,et al. Loss of Heterozygosity for 10q22â€"lOqterin Malignant Melanoma Progression' , 1994 .
[204] J. Hepler,et al. Cell signalling diversity of the Gqalpha family of heterotrimeric G proteins. , 2006, Cellular signalling.
[205] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[206] L. Bonetta. Virus, cells and videotape , 2002, Nature Medicine.
[207] A. Sober,et al. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene. , 1998, Cancer research.
[208] C. Marshall,et al. Control of the ERK MAP kinase cascade by Ras and Raf. , 1996, Cancer surveys.
[209] M. Wigler,et al. Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[210] D. Schadendorf,et al. Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .